Brief: Corline Biomedical Renegotiates Deal With Imperative Care
Nov 20 (Reuters) - Corline Biomedical AB CLBIO.ST :
* RENEGOTIATES AGREEMENT WITH IMPERATIVE CARE TO BROADEN CUSTOMER REACH IN NEUROVASCULAR
CHS™
APPLICATIONS
* BELIEVES THAT THE POTENTIAL FOR CHS™ IN NEUROVASCULAR FIELD AMOUNTS TO AT LEAST SEK 150
MILLION
IN ANNUAL REVENUE
Source text: ID:nGNE7FdbfR
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln